Alzamend Neuro, Inc. (ALZN) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Alzamend Neuro, Inc. (ALZN) Earnings Overview
As of June 28, 2026, Alzamend Neuro, Inc. (ALZN) reported trailing twelve-month net income of -$7M, reflecting +91.4% year-over-year growth. The company earned $-1.85 per diluted share over the past four quarters.
Looking at the long-term picture, ALZN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$69,456 in fiscal 2016.
Alzamend Neuro, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), ANVS (-$41M net income), PRAX (-$327M net income), ALZN has comparable earnings metrics. Compare ALZN vs SAVA →
ALZN Earnings vs Peers
Earnings metrics vs comparable public companies
ALZN Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$5M | +54.6% | -$4M | $-11.32 | - | - |
| 2024 | -$10M | +33.1% | -$10M | $-132.33 | - | - |
| 2023 | -$15M | -20.4% | -$15M | $-205.97 | - | - |
| 2022 | -$12M | -144.9% | -$12M | $-187.31 | - | - |
| 2021 | -$5M | -14.4% | -$5M | $-93.78 | - | - |
| 2020 | -$4M | +9.3% | -$4M | $-83.56 | - | - |
| 2019 | -$5M | -421.7% | -$5M | $-111.56 | - | - |
| 2018 | $-932,000 | +40.6% | $-898,000 | $-27.71 | - | - |
| 2017 | -$2M | -2160.4% | -$2M | $-73.59 | - | - |
| 2016 | $-69,456 | - | $-69,456 | $0.00 | - | - |
Download Data
Export ALZN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALZN — Frequently Asked Questions
Quick answers to the most common questions about buying ALZN stock.
What is ALZN earnings per share (EPS)?
ALZN trailing twelve-month (TTM) diluted EPS is $-1.85, reflecting +91.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Alzamend Neuro, Inc.'s net income?
Alzamend Neuro, Inc. (ALZN) trailing twelve-month net income is $-7M as of 2025. Earnings grew +91.4% year-over-year.
Is ALZN profitable?
ALZN is not currently profitable on a TTM basis, reporting a net loss of $-7M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ALZN's earnings growth rate?
ALZN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are ALZN's profit margins?
Alzamend Neuro, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -657.2%.
Is ALZN growing earnings?
Yes, ALZN earnings are accelerating — EPS growth of +91.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-7M. Earnings momentum is strengthening.
What was ALZN's best earnings year?
Alzamend Neuro, Inc.'s highest annual net income on record is $-69456.00, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were ALZN's earnings last quarter?
ALZN's most recent reported quarter was Q3 2026. Net income was $-2M with diluted EPS of $-0.58. For a full breakdown of all quarters, see the quarterly earnings table on this page.